Genzyme Warned Over Procedures At Drug Plant

Law360, New York (March 10, 2009, 12:00 AM EDT) -- The U.S. Food and Drug Administration has threatened to withhold approval of Genzyme Corp.'s drug shipments and to delay approval of its drug Lumizyme, a treatment for Pompe disease, after inspections revealed “significant deviations” from manufacturing protocols at a Massachusetts plant.

The FDA's warning letter detailing those deviations, sent to Genzyme on Feb. 27, was posted to the agency's Web site on Tuesday. They were discovered during a routine inspection of the company's manufacturing facility in Allston, Mass., in September and October 2008.

The letter cited...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.